PT3514172T - Imunorrecetores específicos de claudina-6 e epítopos de células t - Google Patents

Imunorrecetores específicos de claudina-6 e epítopos de células t

Info

Publication number: PT3514172T
Authority: PT; Portugal
Prior art keywords: immunorrectectors; claudine; specific; cell epitopes; epitopes
Prior art date: 2014-04-01

Application number

PT191512383T

Other languages

English (en)

Original Assignee

Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh

Biontech Cell & Gene Therapies Gmbh

Ganymed Pharmaceuticals Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-01

Filing date

2015-03-30

Publication date

2020-04-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52745896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3514172(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-03-30 Application filed by Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh, Biontech Cell & Gene Therapies Gmbh, Ganymed Pharmaceuticals Gmbh filed Critical Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh

2020-04-21 Publication of PT3514172T publication Critical patent/PT3514172T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Cell Biology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Microbiology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Hospice & Palliative Care (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)

PT191512383T 2014-04-01 2015-03-30 Imunorrecetores específicos de claudina-6 e epítopos de células t PT3514172T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP2014000868		2014-04-01
EP2014072864		2014-10-24

Publications (1)

Publication Number	Publication Date
PT3514172T true PT3514172T (pt)	2020-04-21

Family

ID=52745896

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PT15712657T PT3126381T (pt)	2014-04-01	2015-03-30	Imunorrecetores e epítopos de células t específicos da claudina-6
PT191512383T PT3514172T (pt)	2014-04-01	2015-03-30	Imunorrecetores específicos de claudina-6 e epítopos de células t
PT201601416T PT3708579T (pt)	2014-04-01	2015-03-30	Imunorrecetores e epitopos de células t específicos para claudina-6

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT15712657T PT3126381T (pt)	2014-04-01	2015-03-30	Imunorrecetores e epítopos de células t específicos da claudina-6

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT201601416T PT3708579T (pt)	2014-04-01	2015-03-30	Imunorrecetores e epitopos de células t específicos para claudina-6

Country Status (21)

Country	Link
US (3)	US10370423B2 (pt)
EP (3)	EP3708579B1 (pt)
JP (3)	JP6726656B2 (pt)
CN (3)	CN113150109A (pt)
AU (3)	AU2015239683B2 (pt)
CA (1)	CA2942459C (pt)
CY (1)	CY1121539T1 (pt)
DK (3)	DK3126381T4 (pt)
ES (3)	ES2784537T3 (pt)
FI (1)	FI3708579T3 (pt)
HR (2)	HRP20240926T1 (pt)
HU (3)	HUE044515T2 (pt)
LT (2)	LT3708579T (pt)
ME (1)	ME03407B (pt)
MX (1)	MX376026B (pt)
PL (3)	PL3514172T3 (pt)
PT (3)	PT3126381T (pt)
RS (2)	RS58627B2 (pt)
SI (3)	SI3708579T1 (pt)
SM (1)	SMT201900262T1 (pt)
WO (1)	WO2015150327A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT2499161T (lt) *	2009-11-11	2017-11-27	Ganymed Pharmaceuticals Gmbh	Specifiniai antikūnai, skirti klaudinui 6 (cldn6)
ES2992753T3 (en)	2012-08-24	2024-12-17	Univ California	Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
BR112016010169A2 (pt)	2013-11-06	2017-12-05	Stemcentrx Inc	anticorpos anticlaudina e métodos de uso
MA40921A (fr) *	2014-11-05	2017-09-12	Abbvie Stemcentrx Llc	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
WO2016077525A2 (en) *	2014-11-14	2016-05-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Anti-human thyroglobulin t cell receptors
CN106146666B (zh) *	2015-03-26	2019-09-06	科济生物医药（上海）有限公司	靶向cldn6的免疫效应细胞及其制备方法和应用
WO2016180467A1 (en) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
WO2016180468A1 (en) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Claudin-18.2-specific immunoreceptors and t cell epitopes
IL255697B2 (en)	2015-05-18	2023-11-01	Tcr2 Therapeutics Inc	Compositions and methods for TCR programming using fusion proteins
SG10202002131PA (en)	2015-05-21	2020-05-28	Harpoon Therapeutics Inc	Trispecific binding proteins and methods of use
GB201607534D0 (en)	2016-04-29	2016-06-15	Immunocore Ltd & Adaptimmune Ltd	Peptides
GB201520550D0 (en)	2015-11-23	2016-01-06	Immunocore Ltd & Adaptimmune Ltd	Peptides
GB201520568D0 (en)	2015-11-23	2016-01-06	Immunocore Ltd	Peptides
CN114028549A (zh)	2016-02-19	2022-02-11	伊玛提克斯生物技术有限公司	用于nhl和其他癌症免疫治疗的新型肽和肽组合物
GB201602918D0 (en) *	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
SG10202012157QA (en) *	2016-06-07	2021-01-28	Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft	Chimeric antigen receptor and car-t cells that bind bcma
KR20240113990A (ko)	2016-06-27	2024-07-23	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	암 치료 조합
KR20240017129A (ko)	2016-07-14	2024-02-06	젠맵 에이/에스	Cd40 및 cd137에 대한 다중특이적 항체
IL292551B2 (en) *	2016-10-07	2023-10-01	Tcr2 Therapeutics Inc	Preparations and methods for reprogramming T-cell receptors using fusion proteins
MX2019006374A (es)	2016-12-02	2019-09-11	Univ Southern California	Receptores inmunes sinteticos y metodos de usos de ellos.
AU2018234830B2 (en) *	2017-03-15	2023-03-02	Fred Hutchinson Cancer Center	High affinity MAGE-A1-specific TCRs and uses thereof
RU2770002C2 (ru) *	2017-03-27	2022-04-14	Нойл-Иммьюн Байотек, Инк.	Химерный антигенный рецептор
KR20250020679A (ko)	2017-08-04	2025-02-11	젠맵 에이/에스	Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
MX2020002921A (es) *	2017-09-18	2020-09-28	Univ California	Anticuerpos para claudin6 y métodos para tratar el cáncer.
IL273471B2 (en)	2017-09-29	2023-09-01	Daiichi Sankyo Co Ltd	Conjugation of an antibody with a pyrrolobenzodiazepine derivative
WO2020061482A1 (en)	2018-09-21	2020-03-26	Harpoon Therapeutics, Inc.	Egfr binding proteins and methods of use
WO2020094744A1 (en)	2018-11-06	2020-05-14	Genmab A/S	Antibody formulation
AU2019377553A1 (en) *	2018-11-09	2021-05-27	Fred Hutchinson Cancer Center	T cell receptors specific for mesothelin and their use in immunotherapy
CN113260633A (zh) *	2018-12-05	2021-08-13	豪夫迈·罗氏有限公司	用于癌症免疫疗法的诊断方法和组合物
CN113727720A (zh) *	2019-02-08	2021-11-30	生物技术细胞和基因治疗公司	用于治疗表达cldn6的癌症的嵌合抗原受体修饰的细胞
CN114174829A (zh) *	2019-03-01	2022-03-11	磨石生物公司	T细胞受体的选择
JP7682798B2 (ja)	2019-03-20	2025-05-26	ザリージェンツオブザユニバーシティオブカリフォルニア	クローディン６抗体及び薬物複合体
WO2021129927A1 (en) *	2019-12-23	2021-07-01	Biontech Cell & Gene Therapies Gmbh	Treatment with immune effector cells engineered to express an antigen receptor
WO2021156326A1 (en)	2020-02-04	2021-08-12	Genmab A/S	Antibodies for use in therapy
US20230399403A1 (en)	2020-11-11	2023-12-14	BioNTech SE	Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
US20240216427A1 (en) *	2020-12-30	2024-07-04	St. Jude Children's Research Hospital, Inc.	Chimeric antigen receptors targeting splice variants of the extracellular matrix proteins tenascin c (tnc) and procollagen 11a1 (col11a1)
IL309319A (en)	2021-06-21	2024-02-01	Genmab As	Combined dosage regimen CD137 and PD-L1 binding agents
US20240327544A1 (en)	2021-07-13	2024-10-03	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4395823A4 (en) *	2021-09-03	2025-07-16	Novarock Biotherapeutics Ltd	BISPECIFIC BINDING PROTEINS THAT BIND TO CD137 AND A TUMOR-ASSOCIATED ANTIGEN
WO2023057534A1 (en)	2021-10-06	2023-04-13	Genmab A/S	Multispecific binding agents against pd-l1 and cd137 in combination
IL311901A (en)	2021-10-06	2024-06-01	BioNTech SE	Multiple specific binding agents against PD-L1 and CD137 in combination therapy
CA3234897A1 (en) *	2021-10-14	2023-04-20	Kunle Odunsi	Compositions and methods for use of recombinant t cell receptors against claudin 6
JP2025516590A (ja)	2022-05-12	2025-05-30	ビオンテック・ソシエタス・エウロパエア	プログラム死－１タンパク質に対するモノクローナル抗体および医薬におけるその使用
WO2023218046A1 (en)	2022-05-12	2023-11-16	Genmab A/S	Binding agents capable of binding to cd27 in combination therapy
IL316632A (en)	2022-05-12	2024-12-01	Genmab As	Binding agents capable of binding to CD27 in combination therapy
CN115232207B (zh) *	2022-05-19	2023-06-13	河南大学	抗体-溶菌素（SM-ScFv-Fc-Ly）在治疗变形链球菌感染中的应用
WO2024165057A1 (en) *	2023-02-07	2024-08-15	LaNova Medicines Limited	Antibodies and antibody-drug conjugates targeting claudin 6
WO2024209072A1 (en)	2023-04-06	2024-10-10	Genmab A/S	Multispecific binding agents against pd-l1 and cd137 for treating cancer
US12403202B2 (en)	2023-05-25	2025-09-02	The Regents Of The University Of California	Dosage of claudin-6 conjugates for cancer treatment
WO2025114541A1 (en)	2023-11-30	2025-06-05	Genmab A/S	Antibodies capable of binding to ox40 in combination therapy
WO2025184170A1 (en)	2024-02-27	2025-09-04	Overt Bio, Inc.	Methods and compositions for improving t cell function in an immunosuppressive environment
CN118812714B (zh) *	2024-08-21	2025-05-27	广州百吉生物制药有限公司	一种紧密连接蛋白抗体b3及其应用
CN119320451B (zh) *	2024-08-21	2025-05-16	百吉生物医药(广州)股份有限公司	一种紧密连接蛋白抗体d03及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5677139A (en)	1995-04-21	1997-10-14	President And Fellows Of Harvard College	In vitro differentiation of CD34+ progenitor cells into T lymphocytes
WO1997024447A1 (en)	1996-01-02	1997-07-10	Chiron Corporation	Immunostimulation mediated by gene-modified dendritic cells
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US7435596B2 (en) *	2004-11-04	2008-10-14	St. Jude Children's Research Hospital, Inc.	Modified cell line and method for expansion of NK cell
WO2007034489A2 (en) *	2005-09-22	2007-03-29	Yeda Res & Dev	Immunogenic fragments of t-cell receptor constant domains and peptides derived therefrom
JP5632582B2 (ja)	2006-12-14	2014-11-26	中外製薬株式会社	抗Ｃｌａｕｄｉｎ３モノクローナル抗体およびそれを用いる癌の治療および診断
EP2138576A4 (en) *	2007-03-16	2011-02-23	Kyowa Hakko Kirin Co Ltd	ANTI-CLAUDIN-4 ANTIBODY
EP3064512B1 (en) *	2008-01-11	2023-08-30	The University of Tokyo	Anti-cldn6 antibody
JP5808254B2 (ja)	2009-02-20	2015-11-10	ガニメドファーマシューティカルズアーゲー	癌の診断および治療のための方法および組成物
LT2499161T (lt)	2009-11-11	2017-11-27	Ganymed Pharmaceuticals Gmbh	Specifiniai antikūnai, skirti klaudinui 6 (cldn6)
EP2322555A1 (en) *	2009-11-11	2011-05-18	Ganymed Pharmaceuticals AG	Antibodies specific for claudin 6 (CLDN6)
WO2011113546A1 (en) *	2010-03-16	2011-09-22	Biontech Ag	Tumor vaccination involving a humoral immune response against self-proteins
CN102959078B (zh) *	2010-04-13	2016-01-20	西格马-奥尔德里奇有限责任公司	内源启动子在表达异源蛋白中的用途
EP2404936A1 (en)	2010-07-06	2012-01-11	Ganymed Pharmaceuticals AG	Cancer therapy using CLDN6 target-directed antibodies in vivo
NO3012268T3 (pt) *	2010-09-08	2018-04-14
DK2707390T3 (en) *	2011-05-13	2016-02-29	Ganymed Pharmaceuticals Ag	ANTIBODIES TO TREAT CANCER EXPRESSING CLAUDIN 6
CA2863799C (en)	2012-02-22	2020-09-01	Matthew J. FRIGAULT	Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer

2015
- 2015-03-30 CA CA2942459A patent/CA2942459C/en active Active
- 2015-03-30 PT PT15712657T patent/PT3126381T/pt unknown
- 2015-03-30 ES ES19151238T patent/ES2784537T3/es active Active
- 2015-03-30 HR HRP20240926TT patent/HRP20240926T1/hr unknown
- 2015-03-30 DK DK15712657.4T patent/DK3126381T4/da active
- 2015-03-30 PT PT191512383T patent/PT3514172T/pt unknown
- 2015-03-30 LT LTEP20160141.6T patent/LT3708579T/lt unknown
- 2015-03-30 SI SI201532019T patent/SI3708579T1/sl unknown
- 2015-03-30 PL PL19151238T patent/PL3514172T3/pl unknown
- 2015-03-30 HU HUE15712657 patent/HUE044515T2/hu unknown
- 2015-03-30 FI FIEP20160141.6T patent/FI3708579T3/fi active
- 2015-03-30 DK DK20160141.6T patent/DK3708579T3/da active
- 2015-03-30 DK DK19151238.3T patent/DK3514172T3/da active
- 2015-03-30 EP EP20160141.6A patent/EP3708579B1/en active Active
- 2015-03-30 ES ES20160141T patent/ES2982838T3/es active Active
- 2015-03-30 ME MEP-2019-67A patent/ME03407B/me unknown
- 2015-03-30 RS RS20190361A patent/RS58627B2/sr unknown
- 2015-03-30 JP JP2017503063A patent/JP6726656B2/ja active Active
- 2015-03-30 SM SM20190262T patent/SMT201900262T1/it unknown
- 2015-03-30 PT PT201601416T patent/PT3708579T/pt unknown
- 2015-03-30 HU HUE19151238A patent/HUE050355T2/hu unknown
- 2015-03-30 ES ES15712657T patent/ES2717530T5/es active Active
- 2015-03-30 PL PL15712657T patent/PL3126381T5/pl unknown
- 2015-03-30 SI SI201530629T patent/SI3126381T2/sl unknown
- 2015-03-30 AU AU2015239683A patent/AU2015239683B2/en active Active
- 2015-03-30 RS RS20240864A patent/RS65784B1/sr unknown
- 2015-03-30 EP EP19151238.3A patent/EP3514172B1/en active Active
- 2015-03-30 US US15/124,640 patent/US10370423B2/en active Active - Reinstated
- 2015-03-30 CN CN202110278993.9A patent/CN113150109A/zh active Pending
- 2015-03-30 MX MX2016012713A patent/MX376026B/es active IP Right Grant
- 2015-03-30 EP EP15712657.4A patent/EP3126381B2/en active Active
- 2015-03-30 HU HUE20160141A patent/HUE067504T2/hu unknown
- 2015-03-30 PL PL20160141.6T patent/PL3708579T3/pl unknown
- 2015-03-30 CN CN201580017607.3A patent/CN106459165B/zh active Active
- 2015-03-30 HR HRP20190472TT patent/HRP20190472T4/hr unknown
- 2015-03-30 SI SI201531143T patent/SI3514172T1/sl unknown
- 2015-03-30 CN CN202110279207.7A patent/CN113150110A/zh active Pending
- 2015-03-30 WO PCT/EP2015/056899 patent/WO2015150327A1/en not_active Ceased
- 2015-03-30 LT LTEP15712657.4T patent/LT3126381T/lt unknown
2019
- 2019-04-02 CY CY20191100366T patent/CY1121539T1/el unknown
- 2019-06-18 US US16/444,510 patent/US11345731B2/en active Active
- 2019-07-31 AU AU2019210582A patent/AU2019210582B2/en active Active
2020
- 2020-02-19 JP JP2020025935A patent/JP6985440B2/ja active Active
2021
- 2021-05-31 AU AU2021203528A patent/AU2021203528B2/en active Active
- 2021-11-25 JP JP2021190855A patent/JP7451858B2/ja active Active
2022
- 2022-04-04 US US17/712,562 patent/US20220306711A1/en active Pending

Also Published As

Publication number	Publication date
AU2019210582B2 (en)	2021-03-04
LT3126381T (lt)	2019-05-27
ME03407B (me)	2020-01-20
AU2015239683A1 (en)	2016-09-08
HRP20190472T1 (hr)	2019-06-14
FI3708579T3 (fi)	2024-07-16
PL3126381T5 (pl)	2022-05-23
DK3126381T4 (da)	2022-04-04
LT3708579T (lt)	2024-07-25
RS65784B1 (sr)	2024-08-30
EP3708579A1 (en)	2020-09-16
HRP20190472T4 (hr)	2022-06-24
EP3126381B1 (en)	2019-01-16
HUE044515T2 (hu)	2019-10-28
EP3514172A1 (en)	2019-07-24
HRP20240926T1 (hr)	2024-10-11
ES2784537T3 (es)	2020-09-28
CA2942459A1 (en)	2015-10-08
AU2021203528A1 (en)	2021-07-01
CN106459165B (zh)	2021-04-20
US11345731B2 (en)	2022-05-31
WO2015150327A1 (en)	2015-10-08
DK3126381T3 (en)	2019-04-15
JP2022046462A (ja)	2022-03-23
HUE067504T2 (hu)	2024-10-28
SMT201900262T1 (it)	2019-07-11
SI3708579T1 (sl)	2024-09-30
ES2982838T3 (es)	2024-10-17
JP6985440B2 (ja)	2021-12-22
BR112016022727A2 (pt)	2017-10-31
SI3126381T1 (sl)	2019-07-31
PL3708579T3 (pl)	2024-08-05
PT3126381T (pt)	2019-04-18
ES2717530T5 (es)	2022-05-06
RS58627B1 (sr)	2019-05-31
AU2021203528B2 (en)	2022-10-13
MX376026B (es)	2025-03-07
AU2015239683B2 (en)	2019-08-22
PT3708579T (pt)	2024-07-17
SI3514172T1 (sl)	2020-07-31
PL3514172T3 (pl)	2020-07-27
ES2717530T3 (es)	2019-06-21
EP3708579B1 (en)	2024-05-01
SI3126381T2 (sl)	2022-05-31
CN106459165A (zh)	2017-02-22
BR112016022727A8 (pt)	2018-12-04
RS58627B2 (sr)	2022-06-30
PL3126381T3 (pl)	2019-09-30
EP3126381A1 (en)	2017-02-08
US20190389920A1 (en)	2019-12-26
EP3126381B2 (en)	2022-02-16
DK3514172T3 (da)	2020-04-06
HUE050355T2 (hu)	2020-12-28
JP2020096630A (ja)	2020-06-25
DK3708579T3 (da)	2024-07-22
AU2019210582A1 (en)	2019-08-22
US10370423B2 (en)	2019-08-06
MX2016012713A (es)	2018-03-01
JP6726656B2 (ja)	2020-07-22
JP7451858B2 (ja)	2024-03-19
CN113150109A (zh)	2021-07-23
US20170015720A1 (en)	2017-01-19
CY1121539T1 (el)	2020-05-29
JP2017518762A (ja)	2017-07-13
CA2942459C (en)	2023-03-07
CN113150110A (zh)	2021-07-23
EP3514172B1 (en)	2020-03-11
US20220306711A1 (en)	2022-09-29
NZ723544A (en)	2021-10-29

Publication	Publication Date	Title
PT3514172T (pt)	2020-04-21	Imunorrecetores específicos de claudina-6 e epítopos de células t
IL249313A0 (en)	2017-02-28	Improved t cell compositions
IL251970B (en)	2021-12-01	Anti-cd79b antibodies and methods of use
CL2016002252A1 (es)	2017-06-30	Anticuerpos anti-egfrviii y usos de los mismos
EP3205103C0 (en)	2024-08-14	INTER AND INTRA UNIFICATION BLOCK COPY
EP3693391C0 (en)	2024-08-21	ANTI-CLL-1 ANTIBODIES AND IMMUNOCONJUGATES
DK3229838T3 (da)	2020-10-19	Anti-C10orf54-antistoffer og anvendelser deraf
DK3171891T3 (da)	2025-12-15	Fremgangsmåde
DK3142721T3 (da)	2022-05-30	Kanyleanordning
HUE046000T2 (hu)	2020-01-28	Antiproferatív vegyületek és alkalmazásuk módszerei
LT3097119T (lt)	2021-10-11	Žmogaus antikūnai prieš pd-1
PT3101032T (pt)	2019-04-03	Onjugado de anticorpo anti-her2-fármaco
MA40933A (fr)	2017-09-19	Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
DK3197354T3 (da)	2019-10-07	Medicinsk anordning
DK3116911T3 (da)	2019-09-30	Anti-mcam-antistoffer og tilhørende fremgangsmåder til anvendelse
DK3164088T3 (da)	2021-10-11	Forbedret aterektomiindretning
EP3126132C0 (en)	2024-07-24	EMBOSSING-LAMINATING DEVICE
IL291164A (en)	2022-05-01	Anti-nme antibody
DK3233903T3 (da)	2021-02-22	Kimære antigenreceptorer og anvendelsesfremgangsmåder
DK3110442T3 (da)	2020-12-14	Modificerede meningokok-fhbp-polypeptider
MA40836A (fr)	2017-08-29	Procédures de semi-synthèse
LT3178931T (lt)	2021-04-12	Anti-orai1 antikūnas
LT3126391T (lt)	2020-02-10	Hpa-1a antikūnai
FR3024647B1 (fr)	2017-02-17	Transat de puericulture
DK3183264T3 (da)	2020-11-02	Pegyleringsfremgangsmåde